Feb 18, 2014
From the Healthcare & Life Sciences Institute
This is a critical time for many regulatory affairs departments within life sciences companies, as internal and external forces pressure them to transform their business models.
In order to become lean, nimble and strategic, regulatory affairs departments must quickly “move up” the maturity curve. Doing so will require finding ways to unlock value – evaluating new organizational structures, adopting alternative delivery models and developing end-to-end, integrated capabilities through software vendor partnerships or a consortium with other pharmaceutical companies.